HSA 修订 PRISM 提交指南附录17并更新 MIV 检查清单(2026年9月)
Regulatory Updates for Therapeutic Product Registration
HSA 治疗产品分支修订了 PRISM 提交指南附录17,明确包装配置定义及产品按单一注册或多个包装配置提交的判定指引,附录2A、3A、13A、14A 同步更新,自2026年9月30日起生效。HSA 同时正在审查并更新 Minor Variation(MIV)检查清单,修订版将于2026年11月中旬至12月中旬公开征求意见。
As part of HSA’s ongoing initiative to improve regulatory efficiency and enhance clarity in our regulatory requirements and processes, Therapeutic Products Branch (TPB) is pleased to update industry on the following:
1. Revision of Guidance on PRISM Submission (Appendix 17) (September 2026)
TPB has revised Appendix 17 following the review of feedback received during consultation with industry stakeholders. The revised appendix defines a packaging configuration which describes how a product is supplied, and guidance on how to determine if a product should be submitted as an individual registration or submitted as multiple packaging configurations under a single product registration.
Appendices 2A, 3A, 13A, 14A are also updated to reflect the changes in Appendix 17.
These changes will take effect from 30 September 2026. Please refer to the updated guidance documents for detailed information.
2. Update on MIV checklist revision
HSA is reviewing and updating the Minor Variation (MIV) Checklist. The revised checklist will be published for industry consultation from mid-November to mid-December 2026. Details on the consultation process and feedback submission arrangements will be shared alongside the revised checklist.
来源:HSA 药品质量监管更新 · hsa.gov.sg